Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169

Event · Offering · priced
Instrument
common stock
Gross proceeds
approximately $3,100,000
Shares
169,388 shares
Price per share
$2.04 per share

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 24, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GCTK
Neutral
medium confidence
Mentioned
$GCTK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GCTKNeutralLow
01

Why it matters

The capital raise is intended to fund ongoing development of its investigational device and corporate operations.

02

Market read

A small‑scale equity raise for a micro‑cap biotech; limited immediate market impact.

03

What to watch

Potential strategic partnership with Lōkahi Therapeutics could add long‑term value beyond the immediate cash.

Relevance 6/10Novelty 5/10Timing: offering expected to close on Sep 25, 2026

Background

Glucotrack is a Nasdaq‑listed biotech focused on continuous glucose monitoring technology.

Company-level read

Ticker impact

$GCTKNeutralMedium confidence
Context

Glucotrack announced pricing of a $3.1M public offering of common stock and pre‑funded warrants.

Expected impact

Potential slight downward pressure on GCTK as new shares are issued.

Evidence & confidence

Small raise size relative to market cap suggests limited market impact, but dilution risk may affect price.

Market effects

Minor signal for the diabetes‑monitoring device sector; no broad sector shift.

Limited to US micro‑cap investors.

Low

Counterpoint

The modest raise may be a sign of cash constraints, suggesting caution.

Key entities

  • Glucotrack, Inc.

    Issuer of the public offering.

  • Dawson James Securities, Inc.

    Sole placement agent for the offering.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.